Aussies Greenlight $23B GSK-Novartis Deal With Divestments
The Australian Competition and Consumer Commission on Friday gave its blessing to a three-part, $23 billion deal between GlaxoSmithKline PLC and Novartis AG, provided they divest some products to alleviate antitrust...To view the full article, register now.
Already a subscriber? Click here to view full article